{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-387232","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2026-09-10T11:29:55+00:00","discovered_at":"2026-09-10T11:35:00.439829+00:00","generated_at":"2026-09-10T11:35:27.618306+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prelude Therapeutics gets FDA clearance to start Phase 1 trial of PRT13722 for HR+ breast cancer","bullets":["FDA cleared IND for PRT13722, an oral KAT6A selective degrader, for HR+/HER2- breast cancer.","Phase 1 study expected to begin enrolling patients in Q4 2026.","Study will evaluate PRT13722 as monotherapy and in combination with endocrine and targeted therapies in adults with locally advanced or metastatic HR-positive, HER2-negative breast cancer.","Company believes selective KAT6A degradation may improve efficacy and hematological safety vs dual KAT6A/B inhibitors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-387232","json":"https://secwatch.observer/filing/0001193125-26-387232.json","markdown":"https://secwatch.observer/filing/0001193125-26-387232.md","text":"https://secwatch.observer/filing/0001193125-26-387232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526387232/0001193125-26-387232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526387232/prld-20260910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T11:35:27.618306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}